Teixeira P C, Cutler P, Vuilleumier N
Translational Research Sciences, Basel, Switzerland.
Clin Dev Immunol. 2012;2012:868251. doi: 10.1155/2012/868251. Epub 2012 Nov 20.
Immune-mediated inflammation plays a major role in atherosclerosis and atherothrombosis, two essential features for cardiovascular disease (CVD) development, currently considered as the leading cause of death in the western world. There is accumulating evidence showing that humoral autoimmunity might play an important role in CVD and that some autoantibodies could represent emerging cardiovascular risk factors. Recent studies demonstrate that IgG autoantibodies against apolipoprotein A-1 (apoA-1) are raised in many diseases associated with a high cardiovascular risk, such as systemic lupus erythematosus, acute coronary syndrome, rheumatoid arthritis, severe carotid stenosis, and end-stage renal disease. In this work, we aimed at reviewing current data in the literature pointing to anti-apolipoprotein A-1 antibodies (anti-apoA-1 IgG) as a possible prognostic and diagnostic biomarker of cardiovascular risk and appraising their potential role as active mediators of atherogenesis.
免疫介导的炎症在动脉粥样硬化和动脉粥样硬化血栓形成中起主要作用，这是心血管疾病（CVD）发展的两个基本特征，目前被认为是西方世界的主要死因。越来越多的证据表明，体液自身免疫可能在CVD中起重要作用，并且一些自身抗体可能代表新出现的心血管危险因素。最近的研究表明，在许多与高心血管风险相关的疾病中，如系统性红斑狼疮、急性冠状动脉综合征、类风湿性关节炎、严重颈动脉狭窄和终末期肾病，抗载脂蛋白A-1（apoA-1）的IgG自身抗体水平会升高。在这项工作中，我们旨在回顾文献中的当前数据，这些数据表明抗载脂蛋白A-1抗体（抗apoA-1 IgG）可能是心血管风险的预后和诊断生物标志物，并评估它们作为动脉粥样硬化发生的活性介质的潜在作用。
